Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Omada Health Inc(OMDA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.86
Day High14.37
Open:13.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Omada Health Inc

Select a category then submit the form to load news
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Motley Fool
Omada Health (OMDA) Q4 2025 Earnings Transcript
GlobeNewswire
Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care
GlobeNewswire
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
Tipranks
Barclays Sticks to Its Buy Rating for Omada Health, Inc. (OMDA)
Tipranks
Evercore ISI Sticks to Its Buy Rating for Omada Health, Inc. (OMDA)
GlobeNewswire
Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
GlobeNewswire
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
BayStreet.ca
The 2026 Healthcare Reset: Subscription Economics Meets MRI-Grade AI Precision
Motley Fool
Voyager Stock Up 12% Post-IPO as One Fund Commits Nearly 30% of Assets
Motley Fool
Why a Nearly $30 Million Bet on BETA Stock Says More Than Its 26% Post-IPO Drop
Tipranks
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Omada Health, Inc. (OMDA) and United Therapeutics (UTHR)
Tipranks
Omada Health, Inc. (OMDA) Gets a Hold from Wells Fargo
Tipranks
Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (OMDA), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
GlobeNewswire
Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
GlobeNewswire
Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
Tipranks
Barclays Remains a Buy on Omada Health, Inc. (OMDA)
GlobeNewswire
Omada Health to Participate in J.P. Morgan Healthcare Conference
Tipranks
Evercore ISI Sticks to Their Buy Rating for Omada Health, Inc. (OMDA)
Tipranks
Omada Health, Inc. (OMDA) Receives a Buy from J.P. Morgan
Tipranks
Omada Health Reports Strong Growth and Innovation
Tipranks
Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)
Tipranks
Omada Health Reports Strong Q3 2025 Growth
GlobeNewswire
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
GlobeNewswire
Omada Health Reports Third Quarter 2025 Results
Tipranks
J.P. Morgan Sticks to Its Buy Rating for Omada Health, Inc. (OMDA)
GlobeNewswire
Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer
Tipranks
Omada Health, Inc. (OMDA) Receives a Buy from Barclays
Tipranks
Omada Health added to ‘Tactical Outperform’ list at Evercore ISI
GlobeNewswire
New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions
GlobeNewswire
New Research from Omada Health Demonstrates Significant Cost Savings of Virtual Physical Therapy

Profile

Omada Health Inc. provides a range of virtual care programs principally in the United States. The company offers cardiometabolic programs for prediabetes, diabetes and hypertension; a physical therapy program to address musculoskeletal conditions other support programs. Omada Health Inc. is based in San Francisco, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.